We previously identified loci in the mouse genome that substantially influence the metastatic efficiency of mammary tumors. Here, we present data supporting the idea that the signal transduction molecule, Sipa1, is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Analysis of candidate genes identified a nonsynonymous amino acid polymorphism in Sipa1 that affects the Sipa1 Rap-GAP function. Spontaneous metastasis assays using cells ectopically expressing Sipa1 or cells with knocked-down Sipa1 expression showed that metastatic capacity was correlated with cellular Sipa1 levels. We examined human expression data and found that they were consistent with the idea that Sipa1 concentration has a role in metastasis. Taken together, these data suggest that the Sipa1 polymorphism is one of the genetic polymorphisms underlying the Mtes1 locus. This report is also the first demonstration, to our knowledge, of a constitutional genetic polymorphism affecting tumor metastasis.
The process of metastasis is important in the clinical management of cancer, because most cancer mortality is attributed to metastatic disease rather than the primary tumor 1 . In most cases, individuals with cancer with localized tumors have better prognoses than those with disseminated tumors. But even people with no evidence of tumor dissemination at primary diagnosis are at risk for metastatic disease. Approximately one-third of women with breast cancer who are sentinel lymph node-negative at the time of surgical resection of the primary breast tumor will later develop clinically detectable secondary tumors 2 . Early identification of these individuals might alter management of their disease and improve their prognosis.
To gain a better understanding of the many factors that modulate metastatic progression, our laboratory initiated an investigation into the effects of constitutional genetic polymorphism on metastatic efficiency. Using the polyoma middle-T (PyMT) transgene-induced mouse mammary tumor model 3 , we showed that the genetic background on which a tumor arose influenced its ability to form pulmonary metastases 4 . Quantitative trait genetic mapping analysis identified a probable metastasis efficiency locus, called Mtes1, on proximal mouse chromosome 19 (ref. 5) in a 10-Mb region orthologous to human chromosome 11q12-13, which contains the metastasis suppressor gene Brms1 (ref. 6) . Extensive sequence analysis of mouse Brms1 did not identify any polymorphisms associated with metastatic efficiency suppression 7 , indicating that the causative polymorphism was probably associated with another linked gene.
To identify other potential candidates for underlying Mtes1, a multiple cross mapping (MCM) strategy was used. The MCM strategy 8 takes advantage of shared haplotypes among different inbred strains of mice used in genetic mapping studies to reduce the number of potential candidate genes 9 in a given candidate interval. Using this methodology, a medium-resolution map of the 10-Mb region of mouse chromosome 19 was constructed 10 across four inbred strains used to map the Mtes1 locus. Two strains with high metastatic efficiency (AKR/J and FVB/NJ) and two with low metastatic efficiency (DBA/2J and NZB/B1NJ) were included in the analysis. Identification of five haplotypes blocks that segregated appropriately across the inbred strains reduced the number of high-priority candidate genes from B500 to 23 (ref. 10 ), a more tractable number for further characterization.
Here we describe further analysis of the potential Mtes1 candidate genes identified in previous studies. Using a combination of bioinformatics, sequence analysis and in vitro and in vivo experiments, we identified the signal-induced proliferation-associated gene 1 (Sipa1, also called Spa1; ref. 11) as a strong candidate for underlying the Mtes1 locus.
RESULTS

Sequence analysis of candidate genes
We previously used a multiple cross and haplotypes mapping strategy 8, 12 to identify regions of mouse chromosome 19 that were most likely to contain the gene underlying Mtes1 (ref. 10) . We prioritized five regions containing B23 of the B500 genes present in the original candidate interval for further characterization. We categorized these prioritized genes on the basis of their molecular function, analyzing genes of known function before attempting to analyze the more numerous genes of unknown function. We selected six genes in four of the five haplotype blocks for the first round of analysis. The fifth haplotype block did not contain any genes of interest according to existing knowledge. Three genes in the intervals (Rhod, Map3k11 (also called Mlk3 or Kcnk7) and Sipa1) were members of a signal transduction pathway associated with metastatic progression 13 . None of the prioritized genes were previously associated with metastasis. We also considered three additional genes to be high-priority candidates because of their roles in global gene expression (Htatip and Rela) or DNA damage repair function (Ddb1). Three of these six genes (Rela, Map3k11 and Sipa1) map within the same haplotype block (Fig. 1a) . Two other genes (Pcnxl3 and Kcnk7) also lie in this haplotype block, but these genes are not part of pathways previously associated with metastatic progression or are transcribed exclusively in neuronal tissues and were therefore excluded from the initial analysis. We sequenced the exons, intron-exon boundaries and promoters, as well as 1-2 kb of the regions immediately upstream of the promoters, in the two strains of mice with high metastatic efficiency (AKR/J and FVB/NJ) and the two strains with low metastatic efficiency (DBA/2J and NZB/B1NJ) that were used to construct the haplotypes map 10 . Although we found intronic and silent polymorphisms in Rela, Ddb1, Htatip and Rhod, we observed no obvious functionally relevant polymorphisms in the protein-coding, promoter or upstream regions. Therefore, we excluded these genes from further consideration.
Sequence analysis of the four inbred strains identified a variable tandem repeat (VTR) in the upstream region of Map3k11, containing a variable number of the MMS41 minisatellite tandem repeats 14 . Because VTRs may be associated with alterations in transcriptional activity 15, 16 , we determined the structure of the VTR in the four inbred strains and its effect on the transcriptional and translational activity. PCR amplification across the VTR showed that the number of repeats did not segregate with metastatic efficiency in these four strains (Fig. 1b) . In addition, quantitative RT-PCR and western-blot analyses did not detect substantial differences in either the mRNA levels or the protein levels between the strains (data not shown). Map3k11 was therefore excluded from further analysis. Analysis of Sipa1 identified a polymorphism that results in substitution of an alanine (in strains NZB and DBA) with a threonine (in strains FVB and AKR) in a PDZ domain, a motif frequently implicated in protein-protein interactions 17 . We previously suggested that Mtes1 was associated with the AKR/J allele rather than the DBA/2J allele 7 . Additional analysis 13 showed that this was an error and that the suppression was in fact associated with the DBA/2J allele. We modeled the polymorphism using the software package Cn3D 18 and found that the polymorphism occurs in the open face of an a helix (Fig. 1c) . BLAST analysis 19 showed that the alanine was conserved between mouse and human, suggesting that the threonine substitution might have a functional consequence for protein-protein interactions. Because of the potential functional consequence of this polymorphism, we considered Sipa1 to be a candidate for underlying Mtes1 and subjected it to further characterization.
Functional analysis of Sipa1 polymorphism
Sipa1 is a mitogen-inducible gene that encodes a GTPase-activating protein (GAP) specific for Rap1 and Rap2 GTPases, which are members of the superfamily of Ras-related proteins 20 . Sipa1 therefore negatively regulates Rap through its Rap-GAP activity, which catalyzes the hydrolysis of active GTP-Rap to inactive GDP-Rap. An interaction between the products of human SIPA1 and AQP2, a gene implicated in genetically determined nephrogenic diabetes insipidus, was recently identified 21 . AQP2 is the first protein known to bind the PDZ domain of SIPA1, although the possible influence of this binding on the Rap-GAP activity of SIPA1 has not been examined.
Using AQP2 as a marker protein to monitor binding with the PDZ domain of SIPA1 or Sipa1, we sought to determine whether the efficiency of the interaction might be influenced by the polymorphism identified in the PDZ domain of Sipa1. We transiently transfected COS7 cells, which express very low levels of endogenous AQP2 and Sipa1, with AQP2 and with the DBA allele of Sipa1, the FVB allele of Sipa1 or the human SIPA1 allele (Fig. 2a) . Like the DBA allele, the human allele encodes alanine at the codon corresponding to the polymorphic site in the PDZ domain of Sipa1. When extracts of the transfected cells were immunoprecipitated with an antibody to SIPA1 and then immunoblotted with an antibody to AQP2, the extracts containing the human allele or the Sipa1 DBA allele gave a stronger signal than the extracts containing the FVB allele (Fig. 2a) . Therefore, AQP2 binds the protein encoded by the DBA allele more efficiently than that encoded by the FVB allele.
We then examined whether the Sipa1 polymorphism might influence its in vivo Rap-GAP activity, in the presence or absence of AQP2, in transiently transfected COS7 cells (Fig. 2b) . Mock-transfected cells had low levels of GTP-Rap1 (Fig. 2b) . Therefore, to be able to assess the Rap-GAP activity of Sipa1 in COS7 cells, we cotransfected the cells with Sipa1 and Epac, which encodes a Rap-specific guanine nucleotide exchange factor, which should increase the level of GTP-Rap1 (Fig. 2) . As expected, Epac added without Sipa1 increased the level of GTPRap1 (Fig. 2b) , but the level of GTP-Rap1 was reduced when Sipa1 was added together with Epac. Under these conditions, the human Sipa1 allele was more active than either of the mouse alleles in reducing the level of GTP-Rap1, and the DBA allele was somewhat more active than the FVB allele. We assessed the influence of AQP2 on in vivo Rap-GAP activity by cotransfecting COS7 cells with AQP2 and with Epac and a Sipa1 allele. In cells expressing the human or DBA Sipa1 allele, the presence of AQP2 was associated with roughly a ninefold or a two-to threefold increase, respectively, in the level of GTP-Rap1 compared with the corresponding control cells lacking AQP2 (Fig. 2b) . By contrast, in cells expressing the FVB allele, AQP2 induced less than a 0.5-fold increase.
To confirm that these results could be extended to another cell line, we made stable transfectants of the Sipa1 alleles in U373MG, a human astrocytoma line (Fig. 2c) . We chose this cell line because it contained high levels of endogenous GTP-Rap1 (Fig. 2c) and low levels of endogenous Sipa1 (data not shown). In cells stably transfected with Sipa1, each of the mouse alleles induced a modest reduction in GTPRap1, whereas the human allele induced a more substantial reduction. Transient transfection of these cells with AQP2 resulted in increases in the levels of GTP-Rap1 of roughly twofold in the human allele transfectants and onefold in the DBA allele transfectants. By contrast, AQP2 resulted in levels that were only marginally increased (0.25-fold) in cells expressing the FVB allele.
Taken together, these experiments indicate that expression of AQP2 induces a reduction in the Rap-GAP activity of Sipa1. The increased binding of AQP2 to the DBA allele of Sipa1 relative to the FVB allele results in a greater inhibition of Sipa1 activity, leading to higher concentrations of activated Rap1 (GTP-Rap1) in the DBA transfectants compared with the FVB transfectants (Fig. 2b,c) .
Knock-down of Sipa1 reduces metastatic capacity
To test whether reduction of Sipa1 concentrations reduced metastatic capacity, as predicted by the dominant suppressor hypothesis, we carried out RNA interference (RNAi) knock-down experiments. We were unable to establish cell lines that stably expressed short hairpin RNA (shRNA) with multiple independent single constructs that would knock down mRNA and protein levels for more than B10 d (data not shown). Therefore, we transfected cells from the Mvt1 line, a highly metastatic mammary tumor cell line derived from a MMTV-myc MMTV-vegf double transgenic mouse on an FVB/N genetic background 22 , with two shRNA constructs and isolated individual colonies, resulting in a cell line with a stable reduction of roughly fourfold in Sipa1 mRNA and protein levels (Fig. 3) . We implanted the shRNA knock-down and empty vector control cell lines subcutaneously into virgin FVB/NJ female mice, allowed tumors to grow for four weeks and then examined the lungs for metastases. Macroscopic pulmonary surface metastases were significantly (P o 0.002) reduced in the shRNA knock-down cell line (Fig. 4a) , suggesting that Sipa1 promotes metastasis. The reduction in pulmonary metastases could not be explained by a nonspecific reduction of the proliferative ability of the shRNA knock-down cells, as the primary tumors from the shRNA knock-down line were approximately two times larger than those from the control cell line (Fig. 4b) . The increased growth potential of the Sipa1 RNAi cell line was unexpected, as no substantial difference in growth potential between the FVB and (DBA Â FVB) F 1 hybrids was observed in the original breeding study 4, 5 , suggesting that other modifiers might mask this phenotype in the in vivo experiment 4, 5 .
To determine whether the effects of the RNAi experiments might be due to off-target effects, we examined gene expression data for evidence of interferon induction. We observed no obvious off-target effects (Supplementary Note and Supplementary Table 1 online).
To determine whether there might be compensation for loss of Sipa1 in the cell, we determined the relative intracellular concentrations of the three Rap1 GTPase mRNAs (Sipa1, Sipa1l1 (also called E6TP1; ref. shRNA alters cell morphology and adhesive properties Overexpression of Sipa1 induces detachment of cells from the matrix 11 . Therefore, we examined the RNAi cells to determine whether suppression of Sipa1 levels resulted in increased cell adhesion. Mvt1 control cells transfected with empty vector and grown to confluence consisted of loose sheets of cells with round cells above the monolayer (Fig. 5a) . Sipa1 knock-down cells, in contrast, formed a solid monolayer without rounded or loosely attached cells (Fig. 5b) , suggestive of strong cellular adherence. High-power magnification of the cells also showed a substantial difference in cellular morphology between the clones: Mvt1 control cells had an epithelial morphology, whereas Sipa1 knock-down cells were more spindle-shaped (Fig. 5c,d ).
Sipa1 overexpression increases metastatic capacity If reduction of Sipa1 activity, by either a dominant suppressor allele or a reduction in intracellular level, suppresses metastasis, then overexpression of Sipa1 should enhance metastatic potential. To test this hypothesis, we generated cell lines that overexpress Sipa1. If the reduced rate of metastasis observed in Sipa1 knock-down cell lines is attributable to specific effects on Sipa1 rather than to nonspecific shRNA-induced interferon induction 25 or off-target effects 26 , then overexpression of Sipa1 should enhance the metastatic potential of Mvt1 cells. To test this, we transfected the Mvt1 cell line with a construct encoding the Sipa1 FVB allele with an epitope tag, isolated a clone expressing this construct and implanted it subcutaneously into FVB female mice. We collected lungs after 4 weeks and counted the surface lesions. The cell line ectopically overexpressing Sipa1 developed roughly twice as many surface pulmonary metastases as cell line transfected with empty vector (36.6 versus 16.6; P ¼ 0.0004; Fig. 6 ).
Sipa1 in human metastatic progression
To determine whether Sipa1 has a role in human metastatic progression, we carried out a meta-analysis of human gene expression data. We compared the relative expression of Sipa1 in metastatic versus nonmetastatic tumors using the Oncomine website. Data were available from prostate 27, 28 , lung 29, 30 and a meta-analysis of a variety of solid tumors 31 . Consistent with the data in the mouse breast cancer model, overexpression of Sipa1 was associated with metastatic progression in human prostate cancer (P ¼ 0.001; Fig. 7 ).
DISCUSSION
Many genes have been associated with metastatic progression. Most were identified by differential expression between the primary tumors and the disseminated lesions, mediated by loss of heterozygosity 32 epigenetic modulation 33 or other somatic events. These events are thought to influence metastatic progression by increasing the activity of metastasis-promoting genes or downregulating or abrogating the inhibitory effects of metastasis-suppressing factors. The mouse has been an integral component in the identification of these genes. Introduction of candidate metastasis-associated genes into cell culture followed by introduction of the cells into the lateral tail vein or ectopic or orthotopic implantation is used routinely to assess the effects of particular genes in the establishment of pulmonary metastases. It is believed that the lungs are the primary site of metastasis in mice, unlike humans, because tumor cells are unable to pass through the pulmonary capillary beds owing to the narrow diameter of the pulmonary capillaries. Metastasis to other sites, replicating the diverse metastatic target organs in the human population, can be achieved by introduction of cells into the vasculature in postpulmonary sites (e.g., intracardiac, intrasplenic or portal vein injection 34 ). These strategies have yielded a wealth of information regarding loss or gain of gene functions and the cellular processes that modulate and accompany metastatic progression. Somatic genomic changes resulting in increased or decreased expression of genes are not, however, the only ways to modulate metastasis-associated gene functions. Polymorphism may also influence gene function. The interaction of functional polymorphisms probably underlies most of the nonhereditary cancer susceptibility in the human population. It should not be unexpected, therefore, that similar susceptibility exists for all aspects of tumorigenesis, including metastatic progression. This study represents an ongoing effort in our laboratory to apply the MCM strategy in parallel with conventional quantitative trait locus precision mapping efforts to identify and characterize genes that modify metastatic efficiency (Supplementary Note). Using this strategy, we identified a polymorphism in the signal transduction gene Sipa1 as a candidate for underlying the metastasis efficiency modifier locus Mtes1. Biochemical analysis indicated that the polymorphism, located in the PDZ domain of Sipa1, can influence the known Rap-GAP function of Sipa1, and experimental manipulation of cellular Sipa1 mRNA levels affected the ability of a highly metastatic mammary tumor cell line to colonize the lung. These data suggest that the relative functional concentration of Sipa1, as determined by its overall protein concentration or its availability to inactivate Rap1, modulates metastatic progression. These data also predict that further reduction of functional Sipa1 activity in cells homozygous with respect to the DBA allele, compared with the (DBA Â FVB) F 1 cells that we used, would further reduce metastatic capacity. But it is not possible to carry out these experiments unambiguously; the limitations of meiotic recombination preclude the specific isolation of the Sipa1 DBA allele free of surrounding chromosomal DNA in an otherwise homozygous FVB background. Because there is evidence for at least one other potential candidate gene near Sipa1 contributing to the Mtes1 locus, the results of a congenic experiment could not unambiguously be ascribed to the Sipa1 polymorphism. The ideal experiment would be a knock-in, but the lack of FVB-derived embryonic stem cells precludes carrying out this experiment.
The observation that Sipa1 modulation was effective in a cell line derived from a transgenic mouse other than the PyMT transgenic mouse used in the previous genetic modifier mapping studies 4, 5 suggests that the postulated role of Sipa1 in metastasis is not limited to the particular oncogenic events induced by the PyMT antigen. It remains to be determined how broadly this gene may function in metastatic progression. Our data and the meta-analysis from the Oncomine website suggest that Sipa1 may be important in more than a single cancer type.
The role of Sipa1 in human populations will also require additional studies to resolve. A number of polymorphisms in SIPA1 are present in the public databases, including two nonsynonymous missense mutations near the RAP-GAP domain. Association studies in the Anglian breast cancer cohort 35, 36 identified a possible weak, but not statistically significant, risk of distant metastases in this cohort (data not shown). But SIPA1 has not yet been entirely resequenced, and so additional haplotypes may need to be explored to determine whether polymorphisms in SIPA1 have a role in human breast cancer. The Oncomine data also suggest a possible role in prostate cancer, and studies are underway to validate this result and to examine other solid tumor types.
The precise mechanism by which Sipa1 modulates metastatic efficiency is not known, but our results provide some clues. Sipa1 was originally cloned as a mitogen-inducible protein 37 that was subsequently shown to be a negative regulator of Rap1 by serving as a GAP for Rap1 (ref. 20) . Sipa1 affects cellular adhesion 11 , primarily related to its effects on Rap1, which has been implicated in maintaining the integrity of polarized epithelial 38 and intercellular adherens junctions 39 . Consistent with these activities, we found that knockdown of Sipa1 increased the adhesive properties of Mvt1 cells and eliminated the rounded cells observed in the untransfected cells and empty vector controls (Fig. 5) . Notably, the RNAi knock-down cells also acquired a more spindle-shaped morphology, as compared with the more cuboidal morphology of the control cells, similar to morphological changes observed in other metastasis-suppressed cell systems 40 . Rap1 is also implicated in maintaining the integrity of polarized epithelial 38 and maintenance of intercellular adherens junctions 39 . Part of Sipa1's role in metastasis may therefore be potentiating tumor cells escaping from the primary tumor by modulating cell morphology and the strength of intercellular contacts. In this scenario, the FVB Sipa1 allele would be more active than the DBA allele in promoting lung metastases in the PyMT model, presumably through regulation of Rap1. One might anticipate that modulating cellular adhesion could result in different histologies between tumors with high and low metastatic efficiency. But examination of the tumors by hematoxylin and eosin staining showed no obvious histological differences (R. Cardiff, personal communication), suggesting either that changes in adhesion or cell morphology are not the primary mechanism of Sipa1 metastatic suppression or that the alterations in adhesion or cell morphology do not substantially influence structures at this level of resolution. In addition to activities that promote metastases, Sipa1 may have effects that curtail cell growth and tumor formation, just as Rap1 has activities that may stimulate or inhibit growth 41 . Sipa1 affects cell cycle progression 37, 42 and interacts with a bromodomain protein, Brd4; alterations in the relative ratio of these two proteins disrupted normal cell cycle proliferation 42 . In some contexts, the negative growth functions of Sipa1 may predominate. For example, Sipa1 homozygous knockout mice are viable but eventually develop a myeloproliferative stem cell disorder 43 . The different allelic variants may therefore differentially affect the ability of disseminated cells to enter the cell cycle and proliferate into macroscopic lesions. We have not yet explored this possible effect of the Sipa1 polymorphism.
Our strategy coupled MCM with existing knowledge of gene function to prioritize genes for analysis. Although this approach seems to have been successful in identifying Sipa1 as either underlying the Mtes1 locus or forming a component of this locus, there is no reason to believe that genes of unknown function or known genes in pathways not previously associated with metastasis are not also potential candidates. Our goal in using this method was to eliminate the most obvious and easily testable genes before tackling the more difficult collection of genes of unknown function or functions not thought to be cancer-related. Using other methods to prioritize genes (e.g., gene expression 12 ) would probably identify additional candidate genes. Recent efforts in our laboratory to investigate the Mtes1 locus further, by this and other methods, have identified a second candidate gene of unknown function whose expression correlates with metastatic potential that may contribute to the Mtes1 locus. We are currently investigating the role of this uncharacterized gene in metastatic efficiency.
In conclusion, our data implicate Sipa1 as a strong candidate for underlying Mtes1. To the best of our knowledge, this is the first demonstration that a constitutional genetic polymorphism can influence the metastatic process and strongly supports the idea that genetic background is an important determinant in metastatic progression [44] [45] [46] . Identification of Sipa1 as a component of the metastatic cascade provides insight into the molecular mechanisms that function during tumor progression and provides an additional target to perturb in our efforts to control or eradicate disseminated disease, or one that might eventually serve as a marker for primary tumors at high risk of metastasis.
METHODS
Primers. The sequences of all oligonucleotide primers used in this study are available in Supplementary Table 2 online.
Sequence analysis. We designed sequencing primers using the Primer 3 software package (S. Rozen and H. Skaletsky, Whitehead Institute of Biomedical Research, Cambridge, Massachusetts). We designed primers in intronic sequences to flank exons of interest where possible. We generated PCR products under standard amplification conditions and purified them with Qiagen PCR purification kits. We carried out double-strand sequencing with a Perkin Elmer BigDye Dye Terminator sequence kit. Sequencing was done on a Perkin Elmer 3100 Automated Fluorescent Sequencer. We compiled and analyzed sequences with the computer software packages PHRED and PHRAP 47 .
Quantitative RT-PCR. We transcribed mRNAs into cDNA using ThermoScript RT-PCR System (Invitrogen) in accordance with the manufacturer's protocol. We used SYBR Green Quantitative PCR to detect Sipa1 mRNA levels using an ABI PRISM 7900HT Sequence Detection System. We normalized mRNA levels to Gapdh mRNA levels using primers purchased from Applied Biosystems.
Construction of plasmids. We obtained the FVB Sipa1 construct (IMAGE Clone ID 5324326) from Invitrogen. We constructed pcDNA-fl-sipa1-FVB-neo by inserting the IMAGE cDNA into the vector pcDNA3.1/V5-His TOPO (Invitrogen) and constructed pcDNA-fl-sipa1-DBA-neo by replacing the FVB XbaI-BsrGI fragment with the corresponding fragment from the DBA cDNA. We confirmed the sequences by sequencing with BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems).
We constructed pcDNA-3.1-V5/His-puro and pcDNA-sf-sipa1-FVB-puro plasmids by digesting pcDNA-3.1-V5/His (Invitrogen), pcDNA-fl-sipa1-DBAneo and pcDNA-fl-sipa1-FVB-neo plasmids with NsiI and BstZ17I to replace the neomycin-resistance gene with the analogous SspI and NsiI fragment from the puromycin-resistance gene from pSuper.retro (Oligoengine).
Complex formation between AQP2 and Sipa1. We transiently transfected COS7 cells, using lipofectamine (Invitrogen) in accordance with the manufacturer's instructions, with pcDNA3 vector alone or with pcDNA3-AQP2 (from ATCC) and pSRa-Sipa1 expressing human SIPA1, pcDNA-fl-sipa1-DBA-neo expressing DBA Sipa1 or pcDNA-fl-sipa1-FVB-neo expressing FVB Sipa1. Each dish received the same total amount of DNA. Two days after transfection, we lysed cells with Golden Lysis Buffer containing 20 mM Tris (pH 7.9), 137 mM NaCl, 5 mM EDTA, 1 mM EGTA, 10 mM NaF, 10% glycerol, 1 mM sodium pyrophosphate, 1 mM leupeptin, 1 mM PMSF and 10 mg ml -1 aprotinin. We immunoprecipitated cell extracts with monoclonal antibody to Sipa1 and added protein A/G (PIERCE) with overnight rotation at 4 1C. We washed the immune complexes once with Golden Lysis Buffer, once with high salt HNTG (20 mM Hepes buffer, 500 mM NaCl, 0.1% Triton-X100 and 10% glycerol), and twice with low salt of HNTG (20 mM Hepes buffer, 150 mM NaCl, 0.1% Triton-X100 and 10% glycerol). We then analyzed the immune complexes by immunoblotting with antibody to AQP2 (Santa Cruz). We also analyzed cell extracts from transfectants for protein expression by immunoblotting with the antibody to AQP2 and a monoclonal antibody to Sipa1 (BD BioSciences). For each blot, we used horseradish peroxidase-conjugated antibodies to rabbit, mouse or goat immunoglobulin G for the second reaction at a 1:10,000 dilution. We visualized immune complexes by enhanced chemiluminescence with an ECL Kit (Amersham).
RalGDS pull-down assay. We transiently transfected COS7 cells as described above, except that we also added a plasmid encoding hemagglutinin-tagged Epac to elevate the level of GTP-Rap1. Alternatively, we also transfected an astrocytoma cell line, U373MG, which has high levels of endogenous GTPRap1, with the Sipa1 alleles to establish stable expressing clones. We then transiently transfected these clones with the AQP2-expressing plasmid or vector control. Two days after transfection, we processed cells using a Rap1 activation kit (Upstate Biotech. Inc.) in accordance with the manufacturer's instructions. GTP-Rap1 protein was pulled down by RalGDS beads, washed three times and subjected to gel analysis and immunoblotting with an antibody to Rap1 (Santa Cruz). We also analyzed cell extracts from transfectants as above for protein expression by immunoblotting with antibody to AQP2, monoclonal antibody to Sipa1 or antibody to hemagglutinin (Convance).
Establishment of stable cell lines expressing allelic variants of Sipa1. We used the Mvt1 cell line 22 , derived from a primary mammary tumor in an MMTV-vegf MMTV-myc doubly transgenic mouse, to generate stable cell lines expressing the FVB form of Sipa1. The plasmids pcDNA-3.1-puro, pcDNA-fl-sipa1-DBA-puro or pcDNA-fl-sipa1-FVB-puro were linearized by PmeI digestion and used to transfect Mvt1 cells using Polyfect Transfection Reagent (Qiagen). Twenty-four hours after transfection, we selected the cells in medium containing 10 mg ml À1 puromycin, transferred them to 96-well plates and selected individual clones by limiting dilution. We screened colonies by western blotting against V5 antibody to identify clones expressing full-length Sipa1.
Sipa1 shRNA assays. We generated two different shRNA constructs against Sipa1 by cloning oligonucleotides into the pSuper.Retro.puro vector (Oligoengine). We transfected cells with these plasmids using FuGene (Roche) in accordance with the manufacturer's suggested protocol and selected cells by adding puromycin to the medium to a final concentration of 10 mg ml À1 .
Pulmonary metastasis assays. We cultured cell lines in Dulbecco's modified Eagle Medium (Cellgro) containing 5 mg ml -1 puromycin and 50 mg ml -1 gentamycin and supplemented with 10% fetal bovine serum. Two days before injection, cells were passaged and permitted to grow to 80-90% confluence. We then washed the cells with phosphate-buffered saline, treated them with trypsin, collected them, washed them twice with cold phosphate-buffered saline, counted them in a hemocytometer and resuspended them at a concentration of 2 Â 10 6 cells per ml. We injected 100 ml of cells subcutaneously in the vicinity of the fourth mammary gland into 6-week-old virgin FVB/NJ female mice. Four weeks later, we killed the mice by anesthetic overdose. We dissected and weighed tumors at the injection site. We isolated lungs and counted the surface metastases using a dissecting microscope. These experiments were done in compliance with the National Cancer Institute's Animal Care and Use Committee Guidelines.
